ArticleNature communications2021

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.

Rebekka Duhen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.